[Comparative therapeutic activity of pirprofen and acetylsalicylic acid in rheumatoid arthritis. A 12-month controlled multicenter study].
This double-blind cooperative study comparing pirprofen and acetylsalicylic acid (ASA) in the treatment of rheumatoid arthritis was conducted in 12 centres and involved 342 patients distributed throughout the United States. The patients were randomized to either pirprofen 200 mg four times a day or ASA 900 mg four times a day. The drugs were administered for 52 weeks. Nine standard clinical criteria were used for assessment of the therapeutic results by the investigators and by the patients themselves. Fifty-five % of the total patient population reported that they were highly satisfied with pirprofen, as against 47% with ASA. The investigators preferred pirprofen in 51% of the cases and ASA in 38% (p less than 0.05). Side effects (tinnitus, gastrointestinal disorders) were more frequent in the ASA group than in the pirprofen group. During the 52-week treatment-period, biological alterations were only observed in two patients (1 on pirprofen, 1 on ASA).
D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D010666:Phenylpropionates / Q000009:adverse effects / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D010666:Phenylpropionates; D001241:Aspirin; C008924:pirprofen
Activité thérapeutique comparée du pirprofène et de l'acide acétylsalicylique dans le traitement de la polyarthrite rhumatoïde. Etude multicentrique contrôlée sur douze mois.